Association between \textit{PPARGC1A} single nucleotide polymorphisms and increased risk of nonalcoholic fatty liver disease among Iranian patients with type 2 diabetes mellitus

Leila SAREMI\textsuperscript{1}, Shirin LOTFI\textsuperscript{2}, Masumeh MOHAMMADI\textsuperscript{1}, Hassan HOSEINZADEH\textsuperscript{3}, Zahra HOSEINI-KHAH\textsuperscript{4,5}, Behrooz JOHARI\textsuperscript{6}, Zohreh SALTANATPOUR\textsuperscript{4,7,*}

\textsuperscript{1}Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
\textsuperscript{2}Farhangian University, Shahid Mofatteh Teacher Education Paradise, Tehran, Iran
\textsuperscript{3}Department of Biology, Faculty of Science, Yazd University, Yazd, Iran
\textsuperscript{4}Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
\textsuperscript{5}Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran
\textsuperscript{6}Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
\textsuperscript{7}Medical Genetics Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran

\textbf{1. Introduction}

Nonalcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver disorder in developed countries, and it affects more than 70% of patients with type 2 diabetes mellitus and people suffering from obesity [1,2]. NAFLD is characterized by hepatic and systemic insulin resistance, dyslipidemia, and persistent abnormalities in the liver enzymes [3–5]. NAFLD comprises a broad spectrum of disease severity, ranging from benign hepatocellular steatosis to nonalcoholic steatohepatitis (NASH-fatty changes with inflammation and hepatocellular damages), advanced liver cirrhosis, hepatocellular carcinoma, and increased risk of liver-related mortalities [6].

Inherited factors, along with environmental factors, play an important role in the development of NAFLD [2]. \textit{PPARGC1A} is one of the strongest biological candidate genes for susceptibility to NAFLD. The peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1α) protein is encoded by this gene and plays a role in energy metabolism, including insulin resistance, oxidative phosphorylation, hepatic gluconeogenesis, and mitochondrial biogenesis and respiration, which are important in the development of NAFLD [6]. Moreover, there are some reports regarding the role of PGC-1α in the homeostatic control of systemic energy metabolism, regulation of lipid and carbohydrate metabolism,
development of obesity, and control of blood pressure [7,8].

Recent investigations have indicated that single nucleotide polymorphisms (SNPs) of the PPARGC1A gene may be associated with the susceptibility and progression of NAFLD, obesity, type 2 diabetes mellitus, and hypertension in various ethnicities [9,10]. Previous studies reported an association between PPARGC1A polymorphism at position +1564G/A (rs8192678) with NAFLD, which is associated with the replacement of Gly with Ser (Gly482Ser) [10–12]. However, this polymorphism in the Iranian population has not yet been studied and needs to be explored.

Thus, this study was designed to investigate the association between Gly482Ser polymorphism within the PPARGC1A gene and increased susceptibility to NAFLD in Iranian subjects.

2. Materials and methods
A total of 145 Iranian NAFLD patients and 145 healthy control subjects were recruited to participate in this study. NAFLD was confirmed by liver biopsy in all 145 patients. Exclusion criteria for the NAFLD patients were the presence of either ballooning cells or perisinusoidal/pericellular fibrosis in zone 3 of the hepatic acinus, and lobular inflammation, in addition to steatosis [10]. Moreover, the selection criteria included no history of infections, autoimmunity, alcohol- or drug-induced hepatitis, sclerosing cholangitis, α1-antitrypsin deficiency, primary biliary cirrhosis, hemochromatosis, Wilson’s diseases, or alcohol consumption.

The age- and sex-matched control subjects, who had normal abdominal ultrasonography, were confirmed to have normal liver functions and no metabolic diseases, viral hepatitis, or alcohol abuse. All of the control subjects had normal systolic (<132 mmHg) and diastolic blood pressures (<85 mmHg), total cholesterol levels (<200 mg/dL), fasting glucose (<90–100 mg/dL), and body mass indices (BMIs) (<25 kg/m²). The characteristics of the NAFLD patients and control subjects are presented in Table 1.

Written informed consent was obtained from all participants. The study was approved by the institutional ethics committee and conducted in accordance with the Declaration of Helsinki. The body weights of the participants were measured using a calibrated electronic scale, and venous blood samples were obtained after an overnight fast (12 h). The total serum cholesterol, high-density lipoproteins (HDL), hemoglobin A1c (HbA1c), and triglyceride levels were measured via the enzymatic method (commercial Analco kit, Poland). The low-density

| Characteristics                  | Control    | NAFLD      | P-value |
|----------------------------------|------------|------------|---------|
| Men/women                        | 71/74      | 72/73      | 0.831   |
| Age (years)                      | 51.3 ± 10  | 53.9 ± 9   | 0.423   |
| Weight (kg)                      | 86.3 ± 4.4 | 89.2 ± 3.8 | 0.577   |
| Systolic blood pressure (cmHg)   | 13.12 ± 1.98 | 13.95 ± 2.48 | 0.001 |
| Diastolic blood pressure (cmHg)  | 8.36 ± 0.94 | 8.02 ±1.18  | 0.002   |
| BMI (kg/m²)                      | 24.6 ± 2.6 | 29.4 ± 4.5 | 0.179   |
| FBS (mg/dL)                      | 89.6 ± 13.1 | 182.1 ± 20.3 | 0.572   |
| Total cholesterol (mg/dL)        | 198.8 ± 34.1 | 204.1 ± 28.4 | 0.1     |
| 2h plasma glucose (mg/dL)        | 120.41 ± 12.40 | 240.19 ± 20.15 | 0.012   |
| HDL-C (mg/dL)                    | 45.0 ± 7.3  | 49.0 ± 9.7  | 0.490   |
| LDL-C (mg/dL)                    | 98.03 ± 12.5 | 103.0 ± 21.2 | 0.471   |
| TG (mg/dL)                       | 99 ± 40.4   | 112 ± 36.09 | 0.112   |
| Cr (mg/dL)                       | 0.96 ± 0.2  | 1.02 ± 0.42 | 0.031   |
| HbA1c (%)                        | 6.23 ± 3.0  | 8.63 ± 1.2  | 0.267   |
| Microalbumin (mg/dL)             | 11.12 ± 5.6 | 19.03 ± 6.6 | 0.420   |

Data are mean ± SD; NAFLD: nonalcoholic fatty liver disease, BMI: body mass index, FBS: fasting blood sugar, HDL-C: high-density lipoprotein-cholesterol, LDL-C: low-density lipoprotein-cholesterol, TG: triglycerides, Cr: creatine.
lipoprotein (LDL) cholesterol levels were calculated using the formula of Friedewald [13].

Genomic DNA was isolated from whole blood samples using the Bioneer DNA extraction kit (AccuPrep Genomic DNA Extraction Bioneer Kit, Republic of Korea). Gly482Ser polymorphism genotyping was performed using the amplification refractory mutation system (ARMS)-polymerase chain reaction (PCR) method. The ARMS technique uses allele-specific sequencing primers and the amplification arrest caused by noncomplementary nucleotide(s), located at the 3' end of the primer. In this study, a mutation-specific primer was used, resulting in the formation of an additional product only in the presence of the A allele. A total of 3 primers were used, as follows: two forward primers, 5' GACGAAGCAGACAAGACCG 3' and 5' GACGAAGCAGACAAGACCA 3'; and one common reverse primer, 5' AGAGTTAAAAGAAGAACAAGAAGGAG 3'.

Thermal cycling was carried out under the following conditions: 95 °C for 5 min, and then 30 cycles at 95 °C for 30 s, 56.5 °C for 30 s, and 72 °C for 30 s. This was followed by incubation at 72 °C for 5 min. Agarose gel electrophoresis was used to detect the stained 210-bp PCR products (Figure).

SPSS software (IBM Corp., Armonk, NY, USA) was used for data analysis. Categorical variables including the frequencies of the genotypes and alleles were compared using chi-square analysis and continuous variables by the Student t-test. The odds ratio (OR) and its 95% confidence interval (CI) were calculated to estimate the strength of the association between patients and controls and the polymorphism genotype alleles. Physical and laboratory data are presented as means ± standard deviations (SDs). P < 0.05 was regarded as statistically significant.

3. Results
The genotype and allele frequencies of the Gly482Ser polymorphism are shown in Table 2. Genotypes AA and AG were detected, but no homozygote for the PPARGC1A mutation (GG) was found. The frequency of the AA and AG genotypes in the NAFLD group was 120 and 25, respectively, while in the control group, it was 105 and 40, respectively. Data analysis revealed that the genotypes and alleles in both NAFLD patients and control subjects were in Hardy–Weinberg equilibrium (Table 3). The chi-square test showed a significant difference between the allele frequencies of the Gly482Ser polymorphism among the patients and the controls (P < 0.05). As shown in Table 2, the frequency of A alleles in the NAFLD patients and controls was 265 and 150, respectively, while for the G allele it was 25 and 40. The statistical analysis revealed a significant difference between the groups regarding the PPARGC1A A and G alleles (P = 0.002).

4. Discussion
NAFLD is a major public health problem and a hepatic manifestation of the metabolic syndrome, with an even higher risk in individuals with obesity and type 2 diabetes [1,2]. Patients with NAFLD and type 2 diabetes present...
Table 2. Genotypic association of the Gly482Ser polymorphism with NAFLD.

| Variable          | Genotype | n = 145 | OR (95% CI)         | P-value |
|-------------------|----------|---------|---------------------|---------|
| NAFLD patients    | AA       | 120     |                     |         |
|                   | AG       | 25      | 1.829 (1.04–3.215)  | 0.035   |
| Control subjects  | AA       | 105     |                     |         |
|                   | AG       | 40      |                     |         |
| Variable          | Alleles  |         | OR (95% CI)         | P-value |
| NAFLD patients    | A        | 265     |                     |         |
|                   | G        | 25      | 2.01 (1.41–3.47)    | 0.002   |
| Control subjects  | A        | 250     |                     |         |
|                   | G        | 40      |                     |         |

Table 3. Observed and expected frequencies among the NAFLD patients and control subjects using Hardy–Weinberg equilibrium.

| Groups       | Genotypes | Allele A | Allele G | Observed frequency | Expected frequency | P-value |
|--------------|-----------|----------|----------|--------------------|--------------------|---------|
| NAFLD patients | AA       | 120      | 240      | 0                  | 120                | 121.08  |
|              | AG       | 25       | 25       | 25                 | 25                 | 22.84   |
|              | GG       | 0        | 0        | 0                  | 0                  | 1.08    |
|              | Total    | 145      | 265      | 25                 | 145                | 145.00  |
| Controls     | AA       | 105      | 210      | 0                  | 105                | 107.76  |
|              | AG       | 40       | 40       | 40                 | 40                 | 34.48   |
|              | GG       | 0        | 0        | 0                  | 0                  | 2.76    |
|              | Total    | 145      | 250      | 40                 | 145                | 145.00  |

As shown above, the frequencies of either the genotypes or alleles in both groups were in Hardy–Weinberg equilibrium.

Table 4. Analysis of the physiologic variables in the control and case groups.

| Variable         | Control subjects | NAFLD patients | P-value |
|------------------|------------------|----------------|---------|
|                  | AA               | AG             |         | AA           | AG           |         |
| N                | 105              | 40             | -       | 120          | 25           | -       |
| BMI (kg/m²)      | 24.6 ± 3.5       | 24.5 ± 3.4     | 0.86    | 29.4 ± 4.7   | 29.2 ± 4.4   | 0.75    |
| FBS (mg/dL)      | 89.6 ± 9.1       | 87.4 ± 9       | 0.15    | 190.2 ± 20.2 | 182.1 ± 20.3 | 0.57    |
| Total cholesterol (mg/dL) | 48 ± 1.6 | 44.7 ± 1.7 | 0.2 | 42.2 ± 1.8 | 48.5 ± 1.8 | 0.92 |
| HDL-C (mg/dL)    | 39.7 ± 10.3      | 39.7 ± 11.8    | 0.96    | 52.4 ± 11.9  | 49.7 ± 11.9  | 0.2     |
| LDL-C (mg/dL)    | 50.6 ± 13.3      | 52.4 ± 12      | 0.4     | 88.1 ± 32.2  | 89.9 ± 35.3  | 0.76    |
| TG (mg/dL)       | 76.5 ± 1.5       | 71.9 ± 1.5     | 0.99    | 110.1 ± 2    | 104.2 ± 2    | 0.77    |
| Cr (mg/dL)       | 1 ± 0.3          | 1.1 ± 0.4      | 0.52    | 1 ± 0.3      | 1 ± 0.31     | 0.61    |
| HbA1c (mg/dL)    | 6.8 ± 1.5        | 6.4 ± 1.6      | 0.76    | 8.3 ± 1.9    | 8.5 ± 2      | 0.90    |
| Microalbumin (mg/dL) | 6.3 ± 1.9 | 6.8 ± 2.1 | 0.18 | 20.7 ± 7 | 20.6 ± 6.8 | 0.91 |

Data are shown as mean ± SD; NAFLD: nonalcoholic fatty liver disease, BMI: body mass index, FBS: fasting blood sugar, HDL-C: high-density lipoprotein-cholesterol, LDL-C: low-density lipoprotein-cholesterol, TG: triglycerides, Cr: creatine.
higher levels of complications of diseases, including liver cirrhosis, hepatocellular carcinoma, and death [14].

The protein encoded by the PPARGC1A gene (PGC-1α) is a transcriptional factor that moderates the genes involved in lipid and energy metabolism [10,11]. Previous studies indicated that a deficiency of this protein results in enhanced lipogenesis and hepatic steatosis. PGC-1α interacts with PPAR-α, which is highly expressed in the liver and coordinates the induction of fatty acid oxidation in response to fasting. It also binds to PPAR-γ and activates it to induce the expression of genes that are involved in the differentiation of brown fat tissues. The binding of PGC-1α to PPAR-γ permits the interaction of this protein with multiple transcription factors [15]. PGC-1α also plays a major regulatory role in mitochondria biogenesis and glucose/fatty acid metabolism. Recent studies have suggested the downregulation of PGC-1α-responsive genes in insulin-resistant and type 2 diabetic subjects [16]. Patti et al. analyzed the gene expression of PGC-1α in diabetic Mexican-American subjects. They found that insulin resistance and type 2 diabetes were associated with decreased levels of PGC-1α in the skeletal muscle in both diabetic and family history-positive nondiabetic subjects [6]. Thus, genetic factors that alter the expression of the molecule may participate in the pathogenesis of NAFLD.

In recent years, numerous related case-control gene- and allele-associated studies have investigated the association between single nucleotide polymorphisms and the risk of disease in NAFLD patients. Particularly, a common Gly482Ser polymorphism (rs8192678) of the PPARGC1A gene was reported to be related to the susceptibility of NAFLD in some ethnicities [10]. This polymorphism may reduce PGC-1α activities and/or may change its interaction with other transcription factors required to regulate oxidative stress and lipid metabolism, which finally triggers the pathogenesis of NAFLD in type 2 diabetic subjects. Gly482Ser polymorphism has also been widely reported to be associated with an increased risk of insulin resistance, obesity, and type 2 diabetes in some populations [17–19].

Interestingly, the results of the current investigations confirmed the plausible role of the Gly482Ser polymorphism in the Iranian population. Accordingly, the results revealed that both the AA genotype and A allele were significantly associated with a higher risk of NAFLD. Additionally, based on the statistical analysis, the AA genotype and A allele increased the risk of NAFLD by 1.82- and 2-fold when compared to the AG genotype and G allele, respectively, in Iranian patients with type 2 diabetes. In parallel with our results, several association studies have demonstrated that the Gly482Ser polymorphism increases the susceptibility to NAFLD in type 2 diabetic patients [17–19]. This genotype distribution suggests a significant association between PPARGC1A mutations and NAFLD status. For example, Muller et al. reported that the AA genotype could be associated with early insulin secretion and altered lipid oxidation in a Pima Indian population [18]. SNPs of the PPARGC1A gene were also shown to be related to NAFLD in obese Taiwanese children [3]. Saremi et al. observed that the rs8192678 SNP of the PPARGC1A gene contributed to the onset of type 2 diabetes in Danish patients [4]. However, a study by Hui et al. did not find any association between the Gly482Ser variants and NAFLD in Han Chinese people [20].

Collectively, based on our results, it seems that the AA genotype and A allele can be considered important risk factors for the induction of NAFLD in the Iranian population.

A stratified analysis to assess the impacts of Gly482Ser variations with other known risk factors for NAFLD was accomplished here. For this purpose, the associations of the two genotypes with the physiological and biochemical variables, including BMI, FBS, creatine, TG, plasma lipid levels, HbA1c, and microalbumin levels, were investigated. The results revealed that none of the biochemical parameters were associated with the Gly482Ser polymorphism. Thus, it may be concluded that although Gly482Ser variations were associated with an increased risk of NAFLD in the Iranian population, their role regarding the metabolism of lipids and glucose needs to be explored by further investigation.

The limitation of this study was the low number of diabetic patients with NAFLD available for the analysis. Large-scale well-designed studies, matched case-controls, and functional studies are great tools to support these findings.

In conclusion, the results showed that the PPARGC1A Gly482Ser polymorphism has an impact on NAFLD susceptibility in the Iranian population. As a result, it can be concluded that this gene polymorphism has an important genetic contribution to the etiology of NAFLD in patients with diabetes.

Acknowledgment
This study was supported by the Medical Genetics Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
References

1. Milic S, Mikolasevic I, Krznaric-Zrnic I, Stanic M, Poropat G et al. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Design, Development and Therapy 2015; 9: 4835-4845. doi: 10.2147/DDDT.S64877

2. Moley KH, Colditz GA. Effects of obesity on hormonally driven cancer in women. Science Translational Medicine 2016; 8 (323): 323ps3. doi: 10.1126/scitranslmed.aad8842

3. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006; 29 (6): 1325-1330. doi: 10.2337/dc06-0135

4. Saremi L, Lotfipanah S, Mohammadi M, Hosseinzadeh H, Sayad A et al. Association of HFE gene mutations with nonalcoholic fatty liver disease in the Iranian population. Cellular and Molecular Biology (Noisy-le-Grand) 2016; 62 (12): 123-128. doi: 10.14715/cmb.2016.62.12.2

5. Saremi L, Lotfipanah S, Mohammad M, Hosseinzadeh H, Fathi-Kazerooni M et al. The Pro12Ala polymorphism in the PPAR-y2 gene is not associated with an increased risk of NAFLD in Iranian patients with type 2 diabetes mellitus. 2019; 24 (12). doi: 10.1186/s11658-019-0138-0

6. Dongiovanni P, Rametta R, Fracanzani AL, Benedan L, Borroni V et al. Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology 2010; 10 (102): 102. doi: 10.1186/1471-230X-10-102

7. Portillo-Sanchez P, Cusi K. Treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus. Clinical Diabetes and Endocrinology 2016; 2 (9): 9. doi: 10.1186/s40842-016-0027-7

8. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123 (1): 134-140. doi: 10.1053/gast.2002.34168

9. Adams LA, Lymp JE, St Sauver J, Sanderson SO, Lindor KD et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129 (1): 113-121. doi: 10.1053/j.gastro.2005.04.014

10. Yoneda M, Hotta K, Nozaki Y, Endo H, Uchiyama T et al. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterology 2008; 8 (27): 27. doi: 10.1186/1471-230X-8-27

11. Burguerno AL, Cabrerizo R, Gonzales Mansilla N, Sookoian S, Pirola CJ. Maternal high-fat intake during pregnancy programs metabolic-syndrome-related phenotypes through liver mitochondrial DNA copy number and transcriptional activity of liver PPARGC1A. Journal of Nutritional Biochemistry 2013; 24 (1): 6-13. doi: 10.1016/j.jnutbio.2011.12.008

12. Saremi L, Saremi M, Lotfipanah S, Imani S, Zhang T et al. Relation between PPARGC1A gene polymorphisms with the increased risk of coronary artery disease among patients with type 2 diabetes mellitus in Iran. General Endocrinology 2015; 11 (1): 13-17. doi: 10.4183/aeb.2015.13

13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972; 18 (6): 499-502.

14. Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic fatty liver disease: a clinical update. Journal of Clinical and Translational Hepatology 2017; 5 (4): 384-393. doi: 10.14218/JCTH.2017.00013

15. Liang H, Ward WF. PGC-1α: a key regulator of energy metabolism. Advances in Physiology Education 2006; 30 (4): 145-151. doi: 10.1152/advan.2005.00052.2006

16. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. New England Journal of Medicine 2004; 350: 664-671. doi: 10.1056/NEJMoa031314

17. Hara K, Tobe K, Okada T, Kadowaki H, Akanuma Y et al. A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to type II diabetes. Diabetologia 2002; 45 (5): 740-743. doi: 10.1007/s00125-002-0803-z

18. Muller YL, Bogardus C, Pedersen O, Baier L. A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor gamma coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians. Diabetes 2003; 52 (3): 895-898. doi: 10.2337/diabetes.52.3.895

19. Iff J, Wang W, Sajic T, Oudry N, Gueneau E et al. Differential proteomic analysis of STAT6 knockout mice reveals new regulatory function in liver lipid homeostasis. Journal of Proteome Research 2009; 8 (10): 4511-4524. doi: 10.1021/pr9003272.

20. Hui Y, Yu-Yuan L, Yu-Qiang N, Wei-Hong S, Yan-Lei D et al. Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1α genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver International 2008; 28 (3): 385-392. doi: 10.1111/j.1478-3231.2007.01623.x